LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $18.00

LifeStance Health Group (NASDAQ:LFST) had its target price boosted by BTIG Research from $16.00 to $18.00 in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts have also issued research reports about the stock. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wall Street Zen upgraded shares of LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Canaccord Genuity Group upped their target price on LifeStance Health Group from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Weiss Ratings raised LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. raised their target price on LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, LifeStance Health Group has an average rating of “Moderate Buy” and an average target price of $12.38.

LifeStance Health Group Stock Down 1.4%

Shares of NASDAQ LFST opened at $12.47 on Wednesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. LifeStance Health Group has a 52 week low of $4.77 and a 52 week high of $12.97. The stock has a market capitalization of $4.84 billion, a P/E ratio of 95.93 and a beta of 1.14. The stock’s fifty day moving average is $10.84 and its 200 day moving average is $8.41.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.LifeStance Health Group’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.01) earnings per share. Sell-side analysts forecast that LifeStance Health Group will post 0.16 earnings per share for the current fiscal year.

Insider Activity at LifeStance Health Group

In related news, COO Lisa K. Miller sold 47,912 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.85, for a total value of $519,845.20. Following the completion of the transaction, the chief operating officer owned 281,289 shares of the company’s stock, valued at $3,051,985.65. This represents a 14.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CTO Vukasin Paunovich sold 44,394 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90. Following the completion of the sale, the chief technology officer owned 247,446 shares in the company, valued at $2,684,789.10. This represents a 15.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 14,629,850 shares of company stock valued at $154,952,012 in the last quarter. 3.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently bought and sold shares of the company. Larson Financial Group LLC raised its position in LifeStance Health Group by 19,952.6% in the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after purchasing an additional 3,791 shares during the last quarter. KBC Group NV bought a new stake in shares of LifeStance Health Group during the first quarter worth about $29,000. EverSource Wealth Advisors LLC increased its stake in shares of LifeStance Health Group by 359.1% in the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after buying an additional 5,404 shares during the period. Bayesian Capital Management LP acquired a new position in shares of LifeStance Health Group in the second quarter valued at approximately $52,000. Finally, PNC Financial Services Group Inc. raised its holdings in LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after buying an additional 7,987 shares during the last quarter. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.